优替德隆用于二线及以上转移性乳腺癌的研究进展  

Advances in Utidelone Used as Second- or Later-line Treatment in Metastatic Breast Cancer

作　　者：李晓 孙莹 孙增先 贺飞 Li Xiao;Sun Ying;Sun Zengxian;He Fei(Department of Pharmacy,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100021,China;Department of Pharmacy,the First Affiliated Hospital of Kangda College of Nanjing Medical University)

机构地区：[1]国家癌症中心/国家肿瘤临床医学中心/中国医学科学院北京协和医学院肿瘤医院药剂科,北京100021 [2]南京医科大学康达学院第一附属医院药学部

出　　处：《药物流行病学杂志》2022年第10期700-704,共5页Chinese Journal of Pharmacoepidemiology

摘　　要：优替德隆(UTD1)是通过基因工程改造、微生物发酵而成的新一代埃博霉素类似物,2021年国家药品监督管理局正式批准UTD1上市,作为国内首个埃博霉素类抗肿瘤创新药,其获批适应证为联合卡培他滨,用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。本文对其作用机制、药代动力学特性、临床研究结果、安全性、经济性以及临床使用要点等进行综述,以期为UTD1在转移性乳腺癌中的临床应用提供参考。Utidelone(UTD1) is a new generation of epothilones analogue generated by genetic engineering and microbial fermentation.The National Medical Products Administration officially approved the marketing of UTD1 in 2021,as China’s first epothilones innovative anti-tumor drug,the indications are combination with capecitabine in patients with recurrent or metastatic breast cancer who have received at least one chemotherapy regimen previously.The mechanism of action,pharmacokinetic characteristics,effectiveness,safety and economy of UTD1 were reviewed in this article,hoping to provide references for the clinical application of UTD1 in metastatic breast cancer.

关 键 词：优替德隆 转移性乳腺癌 埃博霉素 微管稳定剂 周围神经毒性 

分 类 号：R979.1[医药卫生—药品]